Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing led by 3E Bioventures Capital and Proxima Ventures Ltd. with participation from Lapam Capital Founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular [...]